Same medication category, different purpose, different outcome
Brand selection requires balancing cost, device comfort, GI side-effects, and a patients ability to store and use injectables safely.[11] For payers and policymakers , it means: There is an opportunity to reduce the cardiometabolic disease burden in India by using medicines that address glucose, weight, and heart risk together
But with the growing necessity for some people and vanity for others, patients are at the mercy of Novo Nordisk, both in terms of availability and the price they pay for these drugs
PlexusDx compounded semaglutide injection, manufactured by licensed 503A compounding pharmacies, delivers the same active pharmaceutical ingredient at a starting price of $149 per monthwith no insurance required, no membership fees, and HSA/FSA eligibility
Two multicenter, randomized, double-blind, placebo-controlled Phase III trials enrolled 168 patients with EPP across the United States and European Union